Asthma is an inflammatory disorder caused by airway exposures to allergens and chemical irritants. Studies focusing on immune, smooth muscle, and airway epithelial function revealed many aspects of the disease mechanism of asthma. However, the limited efficacies of immune-directed therapies suggest the involvement of additional mechanisms in asthmatic airway inflammation. TRPA1 is an irritant-sensing ion channel expressed in airway chemosensory nerves. TRPA1-activating stimuli such as cigarette smoke, chlorine, aldehydes, and scents are among the most prevalent triggers of asthma. Endogenous TRPA1 agonists, including reactive oxygen species and lipid peroxidation products, are potent drivers of allergen-induced airway inflammation in asthma. Here, we examined the role of TRPA1 in allergic asthma in the murine ovalbumin model. Strikingly, genetic ablation of TRPA1 inhibited allergen-induced leukocyte infiltration in the airways, reduced cytokine and mucus production, and almost completely abolished airway hyperreactivity to contractile stimuli. This phenotype is recapitulated by treatment of wild-type mice with HC-030031, a TRPA1 antagonist. HC-030031, when administered during airway allergen challenge, inhibited eosinophil infiltration and prevented the development of airway hyperreactivity. Trpa1 ؊/؊ mice displayed deficiencies in chemically and allergen-induced neuropeptide release in the airways, providing a potential explanation for the impaired inflammatory response. Our data suggest that TRPA1 is a key integrator of interactions between the immune and nervous systems in the airways, driving asthmatic airway inflammation following inhaled allergen challenge. TRPA1 may represent a promising pharmacological target for the treatment of asthma and other allergic inflammatory conditions. airway hyperreactivity ͉ TRP channel ͉ TRPA1
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The airways are densely innervated by peripheral sensory neurons expressing specific receptors activated by noxious chemicals contained in the inhaled air (5) . Over the last decades, evidence has mounted for bi-directional feedback between immunogenic and neurogenic mechanisms in airway inflammation (6, 7) . Neuronal activation causes pain and irritation, neurogenic inflammation, mucus secretion, and reflex responses, such as cough, sneezing, and bronchoconstriction (8, 9) . Members of the transient receptor potential (TRP) superfamily of ion channels play a key role in the response of sensory neurons to inflammatory mediators (10) (11) (12) . The 2 major pro-inflammatory TRP ion channels in sensory neurons are TRPV1, the capsaicin receptor, and TRPA1, activated by mustard oil (13) (14) (15) (16) .
Agonists of TRPV1 and TRPA1, such as capsaicin, acrolein, or chlorine, are potent tussive agents and have been associated with allergic and occupational asthma and reactive airway dysfunction syndrome (RADS) (12, (17) (18) (19) (20) (21) (22) (23) . Potential endogenous TRPA1 agonists include reactive oxygen species, hypochlorite, and lipid peroxidation products (18, (24) (25) (26) . Similar to TRPV1, TRPA1 is activated or sensitized downstream of inflammatory PLC-coupled receptor pathways and mediates inflammatory pain sensitization (12) (13) (14) 27) . In animal models, TRPA1 antagonists block chemically induced inflammatory thermal and mechanical hyperalgesia, neuropathic pain, and diminish acute airway responses to chemical exposures (17, 19, 28) .
The roles of TRPV1 and TRPA1 in asthmatic airway inflammation remain unknown. Using a murine model of acute asthma, we identify a critical role of TRPA1 in this disease. We show that genetic deletion of TRPA1 or pharmacological channel inhibition diminishes allergen-induced inflammatory leukocyte infiltration, mucus production, cytokine and chemokine levels, and airway hyperreactivity. Trpa1 Ϫ/Ϫ mice also show impaired acute and inflammatory neuropeptide release in the airways. In contrast, all aspects of asthmatic airway inflammation were normal in Trpv1 Ϫ/Ϫ mice. These results suggest that TRPA1 is a major neuronal mediator of allergic airway inflammation and may represent a promising target for suppression of inflammation and airway hyperreactivity in asthma.
Results

Diminished Leukocyte Airway Infiltration and Airway Hyperreactivity
in OVA-Challenged Trpa1 ؊/؊ Mice. We used the ovalbumin (OVA) mouse model of asthma to induce a T h 2-directed allergic response, comparing leukocyte levels in the bronchoalveolar lavage fluid (BALF) of OVA-challenged wild-type, Trpa1
Ϫ/Ϫ , and Trpv1 Ϫ/Ϫ mice ( Fig. 1A and B) . Leukocyte numbers were greatly elevated in BALF of OVA-challenged wild-type C57BL/6 mice ( Fig. 1 A) . Eosinophils represented the majority of leukocytes (Fig. 1 A) . In OVA-challenged TRPA1-deficient mice, we observed a remarkable reduction in BALF leukocyte numbers (Ͼ50%), with eosinophilia reduced by Ͼ80% (Fig. 1 A) . In contrast, OVA-challenged Trpv1 Ϫ/Ϫ mice showed robust leukocyte infiltration, with BALF cell counts indistinguishable from those of wild-type mice (Fig. 1B) .
Airway hyperreactivity (AHR) is another important hallmark of asthma. Airway resistance was measured by forced oscillation in response to i.v. administration of increasing concentrations of acetylcholine (Fig. 1C) . OVA-challenged wild-type C57BL/6 mice developed robust AHR (Fig. 1C) . In OVA-challenged Trpa1 Ϫ/Ϫ mice, AHR was very mild, only differing from control animals at the highest doses of acetylcholine. Basal reactivity of vehicle-treated wild-type and Trpa1 Ϫ/Ϫ mice was identical. We conclude that TRPA1 plays an essential role in asthma-related airway hyperreactivity.
Airway eosinophilia and hyperreactivity are consequences of an allergen-induced T h 2-lymphocyte response leading to the production of allergen-specific IgE antibodies. We measured OVA-reactive IgE in serum by EIA to verify whether Trpa1 Ϫ/Ϫ mice produce a normal T h 2-response following immunization and airway challenge with OVA (Fig. 1D) . OVA-reactive IgE serum levels in Trpa1 Ϫ/Ϫ mice were indistinguishable from those in wild-type C57BL/6 mice, suggesting a normal T h 2-dependent systemic immune response to OVA (Fig. 1D ). These data indicate that TRPA1 has a crucial role in later events leading to airway inflammation following allergen challenge.
Quantitative comparison of inflammatory cell densities near airways in lung sections of OVA-challenged mice confirmed diminished eosinophilia in Trpa1 Ϫ/Ϫ mice and reduced hyperplasia of mucus-producing goblet cells (Fig. 1E and supporting information (SI) Fig. S1 A) .
Reduced Mucus Production and Th2 Cytokine Levels in Airways of
OVA-Challenged Trpa1 ؊/؊ Mice. Using quantitative Taqman PCR, we compared the transcriptional levels of the muc5ac mucin genes in whole lung cDNA ( Fig. 2A) . Mucins are mucus proteins highly expressed in asthmatic airways. OVA-challenged wildtype mice displayed robust induction of muc5ac transcription (Fig.  2 A) . In contrast, muc5ac levels were reduced by 50% in lungs of OVA-challenged Trpa1 Ϫ/Ϫ mice (Fig. 2 A) . Mucin5ac induction was normal in OVA-challenged Trpv1 Ϫ/Ϫ mice (Fig. S1B ). T h 2 leukocytes orchestrate the allergic inflammatory response in the airways through the release of cytokines, such as interleukin 5 (IL-5). We examined transcriptional activity of the IL-5 gene by Taqman PCR of whole lung cDNA from wild-type, Trpa1 Ϫ/Ϫ , and Trpv1 Ϫ/Ϫ mice as a measure for T h 2 leukocyte infiltration and activity (Fig. 2B) . Strikingly, while OVAchallenged wild-type mice showed a robust increase in IL-5 transcriptional activity, IL-5 levels in OVA-challenged Trpa1 Ϫ/Ϫ mice were indistinguishable from those in vehicle-treated mice (Fig. 2B ). Trpv1 Ϫ/Ϫ mice showed normal induction of IL-5 expression (Fig. S1C) .
A systematic comparison of peptide concentrations of cytokines and chemokines was performed using Luminex multiplex protein analysis of BAL fluid (Fig. 2C ). As predicted from our qPCR analysis, IL-5 protein levels in BALF of OVA-challenged Trpa1 Ϫ/Ϫ mice were much lower (Ͻ20%) than in wild-type mice (Fig. 2C, Inset) . Trpa1 Ϫ/Ϫ mice also showed significantly diminished levels of IL-13, IL-17, eotaxin, MCP-1, RANTES, and TNF␣, suggesting a profound defect in the T h 2-directed local inflammatory response in the airways (Fig. 2C) . Levels of IFN ␥, an indicator for a T h 1 leukocyte activity, were below the detection limit in all mouse groups, showing that the observed reduction in airway eosinophilia was not due to a shift toward a T h 1-directed immune response in Trpa1
Ϫ/Ϫ mice. Cytokine levels were normally elevated in OVA-challenged Trpv1 Ϫ/Ϫ mice (Fig. S1D) .
A TRPA1 Antagonist Reduces Airway Inflammation and Hyperreactivity when Administered During OVA Airway Challenge. TRPA1-antagonists showed efficacy in animal models of acute and inflammatory pain and diminished the noxious effects of TRPA1 agonists known to cause asthma-related conditions (17, 19, 20, 28, 29) . We asked whether a TRPA1 antagonist would prevent or diminish airway inflammation when administered to OVAsensitized Balb/C mice during the airway challenge phase of the OVA protocol. HC-030031, the most thoroughly studied TRPA1 antagonist, was injected i.p. into OVA-sensitized animals on the day before (200 mg/kg) and twice daily (100 mg/kg) during the 4 days of OVA airway challenge. While vehicle (methyl cellulose, MC)-treated mice showed robust OVA-induced increases in BALF leukocyte numbers, cell numbers were diminished in OVA-challenged HC-030031-treated mice (Fig. 3A) . Moreover, treatment with HC-030031 led to a nearly complete suppression of airway hyperreactivity in OVA-challenged Balb/C mice (Fig.  3B ). Mucin5ac transcription was strongly suppressed by HC-030031 treatment, indicating diminished production of airway mucus (Fig. 3C) . Antagonist-injected mice also showed diminished levels of T h 2 cytokines IL-5 and IL-13 in BALF (Fig. 3D) . Histological sections of airways from antagonist-treated mice showed much lower densities of inflammatory cells (Figs. 3E and  S1E ). Similar to Trpa1 Ϫ/Ϫ mice, treatment with HC-030031 did not affect serum levels of OVA-specific IgE in OVA-challenged wild-type BALB/C mice, indicating a normal T h 2-directed systemic inflammatory response (Fig. S1F) . These data suggest that TRPA1 plays a crucial role in the development of asthma during airway allergen challenge, enabling inflammatory leukocyte infiltration, airway hyperreactivity, and mucus production.
Trpa1 is Essential for Chemically Induced and Inflammatory Neuropep-
tide Release in the Airways. It is unclear whether the proinflammatory action of TRPA1 in asthma can be explained through purely neurogenic effects. TRPA1 may play an as yet undetected role in cells of the immune system or in airway tissue. To assess this possibility, we used Taqman quantitative PCR to compare TRPA1 transcript levels in cDNA derived from spleen harboring a large variety of leukocyte precursors, T h 2 lymphocytes, whole mouse lung and BALF leukocytes of OVAchallenged mice, and DRG. Relative transcript quantities in spleen, T h 2 cells, whole lung, and leukocytes were minimal, with DRG expression several 100-fold higher (Fig. S1G) . Additional qPCR experiments using cDNA prepared from primary leukocytes and leukocyte cell lines failed to detect the presence of TRPA1 cDNA. These results point to a key role for sensory neuronal TRPA1 channels in allergic airway inflammation.
TRPA1 may be a critical trigger for neuropeptide release crucial for leukocyte infiltration and inflammatory progression in asthmatic airways. To investigate this possibility, we compared neuropeptide release in airways of wild-type and and Trpa1 Ϫ/Ϫ mice in response to 2-chloroacetophenone (CN), a potent inflammatory TRPA1 agonist (20) . We performed a 30-s BAL in mice with CN (4 mM) contained in the BAL buffer (PBS) and measured the resultant release of CGRP, substance P (SP) and neurokinin A (NKA) using EIA (Fig. 4 A-C) . CN induced strong increases in the levels of all 3 neuropeptides in BALF of wild-type C57BL/6 mice (Fig. 4 A-C) . In Trpa1 Ϫ/Ϫ mice CNinduced peptide release was clearly diminished (Ͻ50% of wildtype levels), supporting a specific and essential role for TRPA1 in chemically stimulated neurogenic peptide release in the airways (Fig. 4 A-C) . Acute CN-induced neuropeptide release was suppressed by prior treatment with HC-030031 in Balb/C mice (Fig. 4D) .
Exogenous TRPA1 agonists such as CN are likely to mimic the actions of endogenous reactive products and inflammatory signaling pathways activating TRPA1 (16) . Since Trpa1 Ϫ/Ϫ mice showed clear deficiencies in acute neurogenic peptide release in the airways, we asked whether neuropeptide levels would also be reduced during airway allergen challenge. We compared neuropeptide levels in BALF of OVA-challenged wild-type and Trpa1 Ϫ/Ϫ -deficient C57/BL6 mice, and in antagonist treated Balb/C mice, focusing on NK-A, the most abundant neuropeptide in airway lining fluid (30) (Fig. 4 E and F) . Indeed, we observed that the OVA-induced increase in BALF NK-A levels was clearly diminished in Trpa1 Ϫ/Ϫ mice and in antagonisttreated Balb/C mice (Fig. 4 E and F) .
Discussion
Our results reveal a crucial role for the sensory neuronal ion channel TRPA1 in experimental asthma. TRPA1-deficient mice showed profound deficits in airway infiltration by inflammatory leukocytes in the OVA model of allergic airway inflammation, accompanied by a reduction in inflammatory T h 2 cytokines, such as IL-5 and IL-13, and pro-inflammatory chemokines, such as TNF␣ and the eosinophil attractant, eotaxin. As a consequence, OVA-induced mucus production is impaired in Trpa1 Ϫ/Ϫ mice. Airway hyperreactivity, another important hallmark of asthma, was strongly reduced. Pharmacological inhibition of TRPA1 during the airway challenge phase of the OVA protocol confirmed the essential function of this receptor, blocking leukocyte infiltration, cytokine and neuropeptide release, mucus production, and abolishing airway hyperreactivity.
Trpa1 Ϫ/Ϫ mice are deficient in the neuronal detection of multiple pro-inflammatory exogenous and endogenous agents. These include asthma-inducing agents such as chlorine, unsaturated aldehydes in smoke and smog, chloramines, tear gas agents, and industrial isocyanates, as well as endogenous reactive oxidative species and lipid mediators (12, 17-20, 24, 25) . Some of these endogenous mediators are produced by infiltrating leukocytes or inflamed airway tissue and can reach concentrations high enough to chronically activate TRPA1 in airway nerve endings (31) . Chemosensory deficiency in Trpa1 Ϫ/Ϫ mice may cause a lack of neuronal excitation and Ca 2ϩ influx activated by these reactive compounds during inflammatory progression in asthma, resulting in reduced reflex hyperreactivity and neuropeptide release. Indeed, we find that sensory neuropeptide release, a prerequisite for inflammatory leukocyte infiltration in mice, is impaired in the airways of Trpa1 Ϫ/Ϫ mice. This defect applies to both acute neuropeptide release, induced by a TRPA1 agonist, and inflammatory peptide release following OVA challenge in the airways.
The ability of a TRPA1 antagonist to recapitulate the knockout phenotype suggests that TRPA1 fulfills an acute role in promoting local inflammation in the airways, rather than causing a developmental defect in immune system function. Administration of HC-030031 during the OVA airway challenge phase was sufficient to potently suppress airway leukocyte infiltration, mucus production and hyperreactivity. The role of TRPA1 in local inflammatory responses to allergen challenge is also supported by the observation that genetic deletion of TRPA1, or treatment with the TRPA1 antagonist HC-030031, did not seem to affect the systemic T h 2-mediated response to allergen immunization, as evidenced by normal serum levels of OVA-reactive IgE. Future experiments are needed to address the detailed mechanistic role of TRPA1 in neurogenic responses affecting T h 2 lymphocyte migration into the airways, cytokine production, leukocyte recruitment, as well as in airway hyperreactivity.
Our experiments clearly show that TRPV1, the capsaicin receptor, is not required for allergic airway inflammation in the OVA mouse model of asthma. A TRPA1-specific stimulus, possibly a reactive TRPA1-specific mediator, appears to be required to drive the pro-inflammatory activity of airway Cfibers in asthma. Nevertheless, TRPV1 is clearly involved in the symptomatic consequences of airway inflammation, as evidenced by a recent report showing anti-tussive activity of a TRPV1 antagonist in a model of chronic cough (32) .
The data in our present study support the idea that TRPA1 may function as an integrator of chemical and immunological stimuli modulating inflammation in the airways. This integrative activity can explain the pro-inflammatory effects of chemical exposures in asthma patients (16) . By activating TRPA1, chemical irritants may trigger the release of neuropeptides and chemokines in the airways, thereby exacerbating the cellular and tissue inflammatory response observed in our present study. Our study opens an avenue for asthma pharmacology, revealing TRPA1 as a potential target for anti-asthmatic drugs. Future studies will address the action of TRPA1 antagonists in additional animal models of asthma and in other allergic inflammatory conditions.
Materials and Methods
Animals. Experimental procedures were approved by the Institutional Animal Care and Use Committees of Yale University, the University of California, San 
